CMBI Anticipates 707 Drug Value Release to Boost 3SBIO (01530.HK) Growth
Pfizer's Development Plan: Pfizer has announced its development plan for the PD-1/VEGF bispecific antibody 707/PF'4404 in collaboration with 3SBIO, which is expected to exceed market expectations according to CMBI's research report.
Market Positioning: CMBI believes that the PD-1/VEGF bispecific antibody will become a cornerstone in tumor immunotherapy, and Pfizer is likely to leverage its internal pipeline and clinical execution to gain a competitive edge.
Impact on 3SBIO: The global value release of 707/PF'4404 is anticipated to be a significant catalyst for 3SBIO's growth, although CMBI has slightly adjusted its target price for the company from $37.58 to $37.43 while maintaining a Buy rating.
Short Selling Data: Pfizer's stock is experiencing short selling activity with a total of $47.20 million and a ratio of 10.495%, indicating some market skepticism despite the positive outlook on its drug development.
Trade with 70% Backtested Accuracy
Analyst Views on 01530
No data
About the author
CMBI Anticipates 707 Drug Value Release to Boost 3SBIO (01530.HK) Growth
Pfizer's Development Plan: Pfizer has announced its development plan for the PD-1/VEGF bispecific antibody 707/PF'4404 in collaboration with 3SBIO, which is expected to exceed market expectations according to CMBI's research report.
Market Positioning: CMBI believes that the PD-1/VEGF bispecific antibody will become a cornerstone in tumor immunotherapy, and Pfizer is likely to leverage its internal pipeline and clinical execution to gain a competitive edge.
Impact on 3SBIO: The global value release of 707/PF'4404 is anticipated to be a significant catalyst for 3SBIO's growth, although CMBI has slightly adjusted its target price for the company from $37.58 to $37.43 while maintaining a Buy rating.
Short Selling Data: Pfizer's stock is experiencing short selling activity with a total of $47.20 million and a ratio of 10.495%, indicating some market skepticism despite the positive outlook on its drug development.
CICC Reveals Significant H Share Holdings of CN Active Equity Funds in Q4 2025 (Table)
Mainland Chinese Mutual Funds' Holdings: CICC's report highlights the significant changes in Hong Kong stock holdings by Mainland Chinese mutual funds in 4Q25, with notable increases and decreases in various stocks.
Top Stocks with Increased Holdings: CNOOC and China Life saw increases in holdings, while Tencent, Alibaba, and SMIC experienced declines, reflecting varying investor confidence and market conditions.
Short Selling Trends: The report details short selling activities, indicating high ratios for several stocks, including Pop Mart and Kuaishou, suggesting bearish sentiment among investors.
Market Value Changes: The report outlines the market value changes for stocks, with significant losses for companies like Alibaba and Xiaomi, while others like Zijin Mining and YOFC showed gains, indicating a mixed market performance.
HSI Declines 265 Points at Midday as Certain AI and Pharma Stocks Drop; Power Equipment Stocks Rise
Market Overview: The HSI fell 1% to 26,579, with the HSCEI down 0.9% and the HSTECH decreasing by 1.1%, resulting in a total half-day turnover of $132.94 billion.
AI Stocks Performance: XTALPI saw a gain of 3.4%, while KINGSOFT CLOUD, INSILICO, GDS-SW, and UNISOUND experienced declines ranging from 2.7% to 5.6%.
Power Equipment Stocks: DONGFANG ELEC and HARBIN ELECTRIC both rose significantly, with increases of 6.6% and 7.3%, respectively, despite the overall market trend.
Pharmaceutical Sector Decline: Several pharmaceutical stocks, including SINO BIOPHARM and 3SBIO, faced declines of 4.6% to 6.1%, with WUXI APPTEC also dropping by 2.8%.
HSI Rises 268 Points at Midday; BABA-W Jumps Over 3%; Pharmaceuticals in Demand
Market Performance: The NASDAQ Golden Dragon China Index rose over 4%, with Alibaba ADR leading the charge by climbing 10%, contributing to a strong opening for the Hong Kong bourse, which saw the HSI open 350 points higher and close the morning session up 268 points.
Technology Sector Movements: In the technology sector, notable stocks like BABA-W and ALI HEALTH saw gains of 3.5% and 3.3% respectively, while other major players like TENCENT and JD-SW also experienced slight increases, despite some stocks like MEITUAN-W and BIDU-SW declining.
Pharmaceutical Sector Highlights: The 44th JPMorgan Healthcare Conference commenced in San Francisco, with several Chinese pharmaceutical companies participating, leading to significant gains for stocks such as REMEGEN, which surged 11.6%, and CSPC PHARMA, which jumped 5.7% after its innovative drug application was accepted.
AI Concept Stocks Decline: Several AI concept stocks, including SENSETIME-W and WEIMOB INC, experienced declines ranging from 3.3% to 4.2%, while other stocks like KNOWLEDGE ATLAS and MINIMAX-WP saw even steeper drops of 8.8% and 7.5% respectively.
CMBI Ratings and Target Prices for Pharmaceuticals (Table)
Stock Performance: 3SBIO, GUSHENGTANG, SINO BIOPHARM, and WUXI XDC all experienced positive stock price changes, with 3SBIO leading at +6.716%.
Short Selling Data: Significant short selling activity was noted, particularly for SINO BIOPHARM with a ratio of 12.457%, indicating investor caution.
Target Prices: Analysts have set target buy prices for the stocks, with 3SBIO at 37.58, GUSHENGTANG at 44.95, SINO BIOPHARM at 9.4, and WUXI XDC at 74.
Related News: Nomura reported that WUXI APPTEC exceeded expectations in its 4Q25 results, suggesting sustained growth momentum for the current year.
CMBI Anticipates Ongoing Trend in Innovative Drug Exports, Assigns Buy Ratings to SINO BIOPHARM, WUXI XDC, and Others
Performance of MSCI China Health Care Index: The MSCI China Health Care Index has increased by 11.8% year-to-date, surpassing the MSCI China Index's growth of 9.1%, as reported by CMBI.
Factors Driving Pharmaceutical Growth: The rise in the pharmaceutical sector is attributed to a valuation adjustment in Q4 2025 and increased interest from institutional investors at the start of the year.
Future Outlook for Innovative Drugs: The trend of innovative drug exports is anticipated to persist into 2026, with clinical advancements and overseas pipeline data being crucial for growth.
CMBI Ratings on Pharmaceutical Stocks: CMBI has assigned "Buy" ratings to several pharmaceutical companies, including 3SBIO, GUSHENGTANG, WUXI XDC, and SINO BIOPHARM, with detailed ratings and target prices available in a separate table.
CMBI Anticipates 707 Drug Value Release to Boost 3SBIO (01530.HK) Growth
Pfizer's Development Plan: Pfizer has announced its development plan for the PD-1/VEGF bispecific antibody 707/PF'4404 in collaboration with 3SBIO, which is expected to exceed market expectations according to CMBI's research report.
Market Positioning: CMBI believes that the PD-1/VEGF bispecific antibody will become a cornerstone in tumor immunotherapy, and Pfizer is likely to leverage its internal pipeline and clinical execution to gain a competitive edge.
Impact on 3SBIO: The global value release of 707/PF'4404 is anticipated to be a significant catalyst for 3SBIO's growth, although CMBI has slightly adjusted its target price for the company from $37.58 to $37.43 while maintaining a Buy rating.
Short Selling Data: Pfizer's stock is experiencing short selling activity with a total of $47.20 million and a ratio of 10.495%, indicating some market skepticism despite the positive outlook on its drug development.
CICC Reveals Significant H Share Holdings of CN Active Equity Funds in Q4 2025 (Table)
Mainland Chinese Mutual Funds' Holdings: CICC's report highlights the significant changes in Hong Kong stock holdings by Mainland Chinese mutual funds in 4Q25, with notable increases and decreases in various stocks.
Top Stocks with Increased Holdings: CNOOC and China Life saw increases in holdings, while Tencent, Alibaba, and SMIC experienced declines, reflecting varying investor confidence and market conditions.
Short Selling Trends: The report details short selling activities, indicating high ratios for several stocks, including Pop Mart and Kuaishou, suggesting bearish sentiment among investors.
Market Value Changes: The report outlines the market value changes for stocks, with significant losses for companies like Alibaba and Xiaomi, while others like Zijin Mining and YOFC showed gains, indicating a mixed market performance.
HSI Declines 265 Points at Midday as Certain AI and Pharma Stocks Drop; Power Equipment Stocks Rise
Market Overview: The HSI fell 1% to 26,579, with the HSCEI down 0.9% and the HSTECH decreasing by 1.1%, resulting in a total half-day turnover of $132.94 billion.
AI Stocks Performance: XTALPI saw a gain of 3.4%, while KINGSOFT CLOUD, INSILICO, GDS-SW, and UNISOUND experienced declines ranging from 2.7% to 5.6%.
Power Equipment Stocks: DONGFANG ELEC and HARBIN ELECTRIC both rose significantly, with increases of 6.6% and 7.3%, respectively, despite the overall market trend.
Pharmaceutical Sector Decline: Several pharmaceutical stocks, including SINO BIOPHARM and 3SBIO, faced declines of 4.6% to 6.1%, with WUXI APPTEC also dropping by 2.8%.
HSI Rises 268 Points at Midday; BABA-W Jumps Over 3%; Pharmaceuticals in Demand
Market Performance: The NASDAQ Golden Dragon China Index rose over 4%, with Alibaba ADR leading the charge by climbing 10%, contributing to a strong opening for the Hong Kong bourse, which saw the HSI open 350 points higher and close the morning session up 268 points.
Technology Sector Movements: In the technology sector, notable stocks like BABA-W and ALI HEALTH saw gains of 3.5% and 3.3% respectively, while other major players like TENCENT and JD-SW also experienced slight increases, despite some stocks like MEITUAN-W and BIDU-SW declining.
Pharmaceutical Sector Highlights: The 44th JPMorgan Healthcare Conference commenced in San Francisco, with several Chinese pharmaceutical companies participating, leading to significant gains for stocks such as REMEGEN, which surged 11.6%, and CSPC PHARMA, which jumped 5.7% after its innovative drug application was accepted.
AI Concept Stocks Decline: Several AI concept stocks, including SENSETIME-W and WEIMOB INC, experienced declines ranging from 3.3% to 4.2%, while other stocks like KNOWLEDGE ATLAS and MINIMAX-WP saw even steeper drops of 8.8% and 7.5% respectively.
CMBI Ratings and Target Prices for Pharmaceuticals (Table)
Stock Performance: 3SBIO, GUSHENGTANG, SINO BIOPHARM, and WUXI XDC all experienced positive stock price changes, with 3SBIO leading at +6.716%.
Short Selling Data: Significant short selling activity was noted, particularly for SINO BIOPHARM with a ratio of 12.457%, indicating investor caution.
Target Prices: Analysts have set target buy prices for the stocks, with 3SBIO at 37.58, GUSHENGTANG at 44.95, SINO BIOPHARM at 9.4, and WUXI XDC at 74.
Related News: Nomura reported that WUXI APPTEC exceeded expectations in its 4Q25 results, suggesting sustained growth momentum for the current year.
CMBI Anticipates Ongoing Trend in Innovative Drug Exports, Assigns Buy Ratings to SINO BIOPHARM, WUXI XDC, and Others
Performance of MSCI China Health Care Index: The MSCI China Health Care Index has increased by 11.8% year-to-date, surpassing the MSCI China Index's growth of 9.1%, as reported by CMBI.
Factors Driving Pharmaceutical Growth: The rise in the pharmaceutical sector is attributed to a valuation adjustment in Q4 2025 and increased interest from institutional investors at the start of the year.
Future Outlook for Innovative Drugs: The trend of innovative drug exports is anticipated to persist into 2026, with clinical advancements and overseas pipeline data being crucial for growth.
CMBI Ratings on Pharmaceutical Stocks: CMBI has assigned "Buy" ratings to several pharmaceutical companies, including 3SBIO, GUSHENGTANG, WUXI XDC, and SINO BIOPHARM, with detailed ratings and target prices available in a separate table.
